Comparing Firefly Neuroscience (NASDAQ:AIFF) and DarioHealth (NASDAQ:DRIO)

DarioHealth (NASDAQ:DRIO) and Firefly Neuroscience (NASDAQ:AIFF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares DarioHealth and Firefly Neuroscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	N/A	N/A	N/A	($6.13)	-0.57
Firefly Neuroscience	N/A	N/A	N/A	($0.59)	-1.69

Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for DarioHealth and Firefly Neuroscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	3	0	2.40
Firefly Neuroscience	1	0	0	0	1.00

DarioHealth presently has a consensus price target of $9.00, suggesting a potential upside of 158.62%. Given DarioHealth’s stronger consensus rating and higher possible upside, equities analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience.

Profitability

This table compares DarioHealth and Firefly Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	N/A	N/A	N/A
Firefly Neuroscience	N/A	N/A	N/A

Summary

DarioHealth beats Firefly Neuroscience on 4 of the 6 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.